Australia - English - Department of Health (Therapeutic Goods Administration)

accord healthcare pty ltd - glimepiride, quantity: 4 mg - tablet, uncoated - excipient ingredients: magnesium stearate; lactose monohydrate; sodium starch glycollate type a; povidone - glimepiride apotex is indicated as an adjunct to diet, exercise and weight loss to lower the blood glucose in patients with non-insulin-dependent diabetes mellitus (type 2)

Australia - English - Department of Health (Therapeutic Goods Administration)

accord healthcare pty ltd - glimepiride, quantity: 3 mg - tablet, uncoated - excipient ingredients: magnesium stearate; povidone; lactose monohydrate; iron oxide yellow; sodium starch glycollate type a - glimepiride apotex is indicated as an adjunct to diet, exercise and weight loss to lower the blood glucose in patients with non-insulin-dependent diabetes mellitus (type 2)

Australia - English - Department of Health (Therapeutic Goods Administration)

accord healthcare pty ltd - glimepiride, quantity: 1 mg - tablet, uncoated - excipient ingredients: povidone; magnesium stearate; sodium starch glycollate type a; lactose monohydrate; iron oxide red - glimepiride apotex is indicated as an adjunct to diet, exercise and weight loss to lower the blood glucose in patients with non-insulin-dependent diabetes mellitus (type 2)

United States - English - NLM (National Library of Medicine)

nucare pharmaceuticals, inc. - glimepiride (unii: 6ky687524k) (glimepiride - unii:6ky687524k) - glimepiride tablets usp are indicated as an adjunct to diet and exercise to improve glycemic control in adults with type 2 diabetes mellitus [see clinical studies ( 14.1) ] . glimepiride tablets usp should not be used for the treatment of type 1 diabetes mellitus or diabetic ketoacidosis, as it would not be effective in these settings. glimepiride tablets are contraindicated in patients with a history of a hypersensitivity reaction to: -  glimepiride or any of the product’s ingredients [see warnings and precautions ( 5.2)]. sulfonamide derivatives: patients who have developed an allergic reaction to sulfonamide derivatives may develop an allergic reaction to glimepiride. do not use glimepiride in patients who have a history of an allergic reaction to sulfonamide derivatives. reported hypersensitivity reactions include cutaneous eruptions with or without pruritus as well as more serious reactions (e.g., anaphylaxis, angioedema, stevens-johnson syndrome, dyspnea) [see warnings and precautions ( 5.2) and advers

United States - English - NLM (National Library of Medicine)

teva pharmaceuticals usa, inc. - glimepiride (unii: 6ky687524k) (glimepiride - unii:6ky687524k) - glimepiride 1 mg - glimepiride tablets are indicated as an adjunct to diet and exercise to improve glycemic control in adults with type 2 diabetes mellitus [see clinical studies (14.1)]. limitations of use glimepiride tablets should not be used for the treatment of type 1 diabetes mellitus or diabetic ketoacidosis, as it would not be effective in these settings. glimepiride tablets are contraindicated in patients with a history of a hypersensitivity reaction to: - glimepiride or any of the product’s ingredients [see warnings and precautions (5.2)]. - sulfonamide derivatives: patients who have developed an allergic reaction to sulfonamide derivatives may develop an allergic reaction to glimepiride tablets. do not use glimepiride tablets in patients who have a history of an allergic reaction to sulfonamide derivatives. risk summary available data from a small number of published studies and postmarketing experience with glimepiride use in pregnancy over decades have not identified any drug associated risks for major birth defects

Belgium - English - AFMPS (Agence Fédérale des Médicaments et des Produits de Santé)

eg sa-nv - glimepiride 2 mg - tablet - 2 mg - glimepiride 2 mg - glimepiride

Belgium - English - AFMPS (Agence Fédérale des Médicaments et des Produits de Santé)

sandoz sa-nv - glimepiride 2 mg - tablet - 2 mg - glimepiride 2 mg - glimepiride

United States - English - NLM (National Library of Medicine)

physicians total care, inc. - glimepiride (unii: 6ky687524k) (glimepiride - unii:6ky687524k) - glimepiride 1 mg - glimepiride tablets are indicated as an adjunct to diet and exercise to improve glycemic control in adults with type 2 diabetes mellitus (see dosage and administration ). glimepiride tablets are contraindicated in patients with - known hypersensitivity to the drug. - diabetic ketoacidosis, with or without coma. this condition should be treated with insulin.

United States - English - NLM (National Library of Medicine)

aurobindo pharma limited - glimepiride (unii: 6ky687524k) (glimepiride - unii:6ky687524k) - glimepiride 1 mg - glimepiride tablets are indicated as an adjunct to diet and exercise to improve glycemic control in adults with type 2 diabetes mellitus [see clinical studies (14.1)]. limitations of use glimepiride tablets should not be used for the treatment of type 1 diabetes mellitus or diabetic ketoacidosis, as it would not be effective in these settings. glimepiride tablets are contraindicated in patients with a history of a hypersensitivity reaction to: - glimepiride or any of the product’s ingredients [see warnings and precautions (5.2)].   - sulfonamide derivatives: patients who have developed an allergic reaction to sulfonamide derivatives may develop an allergic reaction to glimepiride tablets. do not use glimepiride tablets in patients who have a history of an allergic reaction to sulfonamide derivatives.  risk summary available data from a small number of published studies and postmarketing experience with glimepiride use in pregnancy over decades have not identified any drug associated risks for ma

United States - English - NLM (National Library of Medicine)

virtus pharmaceuticals - glimepiride (unii: 6ky687524k) (glimepiride - unii:6ky687524k) - glimepiride 1 mg - glimepiride tablets are indicated as an adjunct to diet and exercise to improve glycemic control in adults with type 2 diabetes mellitus [see clinical studies (14.1)] . limitations of use glimepiride tablets should not be used for the treatment of type 1 diabetes mellitus or diabetic ketoacidosis, as it would not be effective in these settings. glimepiride tablets are contraindicated in patients with a history of a hypersensitivity reaction to: risk summary available data from a small number of published studies and postmarketing experience with glimepiride tablets use in pregnancy over decades have not identified any drug associated risks for major birth defects, miscarriage, or adverse maternal outcomes. however, sulfonylureas (including glimepiride) cross the placenta and have been associated with neonatal adverse reactions such as hypoglycemia. therefore, glimepiride tablets should be discontinued at least two weeks before expected delivery (see clinical considerations) . poorly controlled diabetes in pre